Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin vs Comparator in Pediatric ABSSSI
NCT02814916Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2017
- Primary completion
- Jan 2024
- Modality
- Peptides, Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of dalbavancin in acute bacterial skin and skin structure infection (ABSSSI), sponsored by AbbVie Inc.. Started Mar 2017; status: completed.
02
Drugs
dalbavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT02814916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02814916.